Bli medlem
Bli medlem

Du är här

2016-05-18

Moberg Pharma: Bulletin from Moberg Pharma's AGM 2016

STOCKHOLM, MAY 18th, 2016. Moberg Pharma AB's ("Company") Annual
General Meeting took place on Wednesday, May 18, 2016 in the
Company's premises in Bromma.

Adoption of the income statements and the balance sheets
The Annual General Meeting (the "Meeting") approved the income
statements and the balance sheets for the fiscal year 2015.

The Meeting resolved, in accordance with the proposal of the Board of
Directors, that no dividend should be paid for the fiscal year 2015.

The Meeting discharged the Board members and the Chief Executive
Officer from liability for the fiscal year 2015.

Board of Directors
In accordance with the proposal of the Nomination Committee, the
Meeting resolved that the Board of Directors shall consist of six
persons and no deputies.

The Meeting resolved re-election of the Board Directors Wenche
Rolfsen, Torbjörn Koivisto, Geert Cauwenbergh, Thomas B. Thomsen,
Thomas Eklund and Mattias Klintemar. Mats Pettersson has decided to
resign as Board Director.

Thomas Eklund was elected as Chairman of the Board of Directors.

The Meeting resolved, in accordance with the proposal of the
Nomination Committee, that an aggregate fee to Board members of SEK
1,250,000 shall be paid, of which SEK 340,000 to the Chairman and SEK
170,000 for all members elected by the Annual General Meeting. It was
also resolved that an additional fee of SEK 60,000 shall be paid to
the Chairman of the Compensation Committee.

Fees to the Auditors, for a period until the end of the next Annual
General Meeting, are to be paid as per approved invoice.

Nomination Committee
The Meeting resolved, in accordance with the proposal of the
Nomination Committee, that the Company shall have a Nomination
Committee consisting of four members. The Nomination Committee shall
comprise one representative of each of the three largest shareholders
or owner groups in the Company in terms of votes as per September 30,
2016, besides the Chairman of the Board of Directors.

Principles for remuneration
The Meeting resolved to approve the Board of Director's proposal for
principles of remuneration to senior executives in Moberg Pharma.

Employee Stock Option Plan 2016
In accordance with the Board of Directors' revised proposal, the
Meeting resolved to adopt an employee stock option plan for employees
in the Company in the Company and in the Company's wholly-owned
subsidiary Moberg Pharma North America LLC. It will be permissible to
allot a maximum of 75,000 employee stock options per plan
participant. The Board of Directors and the Chief Executive Officer
shall decide which persons shall be encompassed by the Employee Stock
Option Plan based on position, qualification and individual
performance. The maximum allotment may be adjusted proportionally
based on each person's time as an employee in the Company and Moberg
Pharma North America LLC, respectively. The employee stock option
plan will include the following senior executives in the Company;
Anna Ljung and Martin Ingman are proposed to be allotted 40,000
employee stock options each, Kjell Rensfeldt is proposed to be
allotted 60,000 employee stock options and Peter Wolpert is proposed
to be allotted 75,000 employee stock options. In order to secure the
Company's commitments under the employee stock option plan, the
Meeting resolved on an issue of a maximum 428,000 warrants to the
Company's wholly-owned subsidiary Moberg Derma Incentives AB. In
addition the Meeting resolved to approve that the subsidiary is
entitled to transfer warrants or shares in the Company to the
participants in the employee stock option plan, or otherwise dispose
of the warrants, in order to secure the Company's commitments and
costs in connection with the employee stock option plan. In the event
that all warrants issued in respect of Employee Stock Option Plan
2016 are used to subscribe for new shares, the Company's share
capital will increase by SEK 42,800 from SEK 1,421,752.20 to SEK
1,464,552.20. This is equivalent to a dilution of approximately 2.9
per cent of the shares and votes in the Company.

Authorization to issue share
The Meeting resolved, in accordance with the proposal of the Board of
Directors, to authorize the Board of Directors to, within the scope
of the articles of association, with or without deviation from the
shareholders' preferential right, on one or several occasions during
the period until the next Annual General Meeting, resolve to increase
the Company's share capital by issuing new shares in the Company. The
total number of shares issued in accordance with this authorization
may be equivalent to a maximum of 20 per cent of the shares in the
Company at the time of the 2016 Annual General Meeting.

About this information
Moberg Pharma discloses the information provided herein pursuant to
the Securities Markets Act and/or the Financial Instruments Trading
Act. The information was submitted for publication at 8:00 pm (CET)
on May 18th, 2016.

For further information, please contact:
Peter Wolpert, CEO, Telephone: +46 707 35 71 35, E-mail:
peter.wolpert@mobergpharma.se

Anna Ljung, CFO, Telephone: +46 707 66 60 30, E-mail:
anna.ljung@mobergpharma.se

About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical
company with OTC sales operations in the U.S. and a distributor
network in more than 40 countries. The company's portfolio includes
the OTC brands Kerasal®, Kerasal Nail®, Balmex®, Domeboro®. Kerasal
Nail®(Emtrix®or Nalox™ in certain markets) is a leading OTC treatment
of nail disorders in the U.S., Canada and several EU markets and is
currently being launched in Southeast Asia. The company is growing
organically as well as through acquisitions. Internal development
programs focuses on innovative drug delivery of proven compounds and
include two clinical stage assets, MOB-015 (onychomycosis) and BUPI
(pain management in oral mucositis). Moberg Pharma has offices in
Stockholm and New Jersey and the company's shares are listed on the
Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX:
MOB).

-----------------------------------------------------------
http://news.cision.com/moberg-pharma/r/bulletin-from-moberg-pharma-s-agm...
http://mb.cision.com/Main/1662/2011095/516880.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.